1. Home
  2. IOVA vs MD Comparison

IOVA vs MD Comparison

Compare IOVA & MD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • MD
  • Stock Information
  • Founded
  • IOVA 2007
  • MD 1979
  • Country
  • IOVA United States
  • MD United States
  • Employees
  • IOVA N/A
  • MD N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • MD Hospital/Nursing Management
  • Sector
  • IOVA Health Care
  • MD Health Care
  • Exchange
  • IOVA Nasdaq
  • MD Nasdaq
  • Market Cap
  • IOVA 1.0B
  • MD 1.1B
  • IPO Year
  • IOVA N/A
  • MD 1995
  • Fundamental
  • Price
  • IOVA $1.75
  • MD $14.53
  • Analyst Decision
  • IOVA Strong Buy
  • MD Buy
  • Analyst Count
  • IOVA 9
  • MD 6
  • Target Price
  • IOVA $15.50
  • MD $17.08
  • AVG Volume (30 Days)
  • IOVA 13.9M
  • MD 729.9K
  • Earning Date
  • IOVA 05-08-2025
  • MD 05-06-2025
  • Dividend Yield
  • IOVA N/A
  • MD N/A
  • EPS Growth
  • IOVA N/A
  • MD N/A
  • EPS
  • IOVA N/A
  • MD N/A
  • Revenue
  • IOVA $212,679,000.00
  • MD $1,976,177,000.00
  • Revenue This Year
  • IOVA $182.20
  • MD N/A
  • Revenue Next Year
  • IOVA $62.10
  • MD $2.76
  • P/E Ratio
  • IOVA N/A
  • MD N/A
  • Revenue Growth
  • IOVA 11070.12
  • MD N/A
  • 52 Week Low
  • IOVA $2.70
  • MD $6.62
  • 52 Week High
  • IOVA $13.60
  • MD $17.67
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 23.78
  • MD 63.62
  • Support Level
  • IOVA $3.02
  • MD $12.17
  • Resistance Level
  • IOVA $3.31
  • MD $12.95
  • Average True Range (ATR)
  • IOVA 0.24
  • MD 0.52
  • MACD
  • IOVA -0.09
  • MD 0.29
  • Stochastic Oscillator
  • IOVA 4.81
  • MD 88.75

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About MD Pediatrix Medical Group Inc.

Pediatrix Medical Group Inc provides physician services to hospitals, intensive care units, and other medical units. The services provided by the company include maternal care for expectant mothers, intensive care for premature babies, cardiology care for infants suffering from heart defects, and anesthesia care during surgeries, among others. The company operates only under one segment which provides physician services including newborn, maternal-fetal, and other pediatric subspecialty care. It generates majority of the revenue through neonatology and other pediatric subspecialties.

Share on Social Networks: